LEH Pharma Ltd
(“LEH Pharma” or the “Company”)

LEH Pharma announces first EyeMax Mono surgery performed in South Africa

Successful lens implantation for both eyes performed in Western Cape, South Africa
EyeMax now available in over 25 countries worldwide

London, UK – 12 September 2018 -- LEH Pharma Ltd, the leading provider of novel ocular implants for macular disorders, today announces that EyeMax Mono lens implant surgery for the treatment of age-related macular degeneration (AMD) has been successfully performed for the first time in South Africa. EyeMax is now being implanted by over 100 surgeons in more than 25 countries around the world.

The EyeMax Mono lens was implanted in both eyes over the course of two separate operations carried out by Dr Nico van Helsdingen at the Cure Day Clinics Somerset West, in Western Cape, South Africa. Further operations with the lens have been planned with other patients for later in September.

AMD affects the central part of the retina and is the leading cause of blindness in people aged over 60, affecting nearly 200 million people worldwide. The unique optics of the EyeMax lens optimises the quality of the image supplied across the macula, permitting patients to make use of functioning areas of retina that would otherwise receive a blurred image. It is the only adequate treatment for all types of AMD, and is delivered through a simple cataract surgery.

Dr Nico van Helsdingen said: “AMD erodes the quality of life of millions around the world, and can make everyday tasks near impossible. I am delighted to have performed the first EyeMaxMono surgery in South Africa, and that sufferers of AMD in this country are now able to access this treatment option. The next operations are already scheduled, and we are hopeful that many more patients will benefit from having their eyesight and quality of life improved.”

Dr Bobby Qureshi, CEO and founder of LEH Pharma, commented: “Our EyeMax Mono lens technology is being rapidly adopted across the world, and with this successful surgery another country has gained access to a treatment for all types of AMD. LEH Pharma is committed to expanding the international reach of its products and services, creating strong relationships with world-leading surgeons and ophthalmology specialists such as Dr van Helsdingen to ensure that more patients have access to this novel treatment.”

Ends

For more information, please contact:

LEH Pharma Ltd
Dr Bobby Qureshi
contact@LEHPharma.com
+ 44 (0) 20 7060 2763

Consilium Strategic Communications
Mary-Jane Elliott, Angela Gray, Chris Welsh
LEHPharma@consilium-comms.com
www.consilium-comms.com
+44 (0) 20 3709 5700

Notes for editors:

About LEH Pharma
LEH Pharma is a leading provider of revolutionary ocular implants for macular disorders. Its disruptive lens technology, which is unique, proven and patented, is currently marketed internationally for the treatment of stable wet and dry AMD. The Company was formed in 2011 by a group of pioneering surgeons, and is supported by a network of world-leading ophthalmologists and scientists.
For more information, please visit LEH Pharma’s website at www.lehpharma.com

About EyeMax
EyeMax is a revolutionary breakthrough for AMD sufferers and is the only adequate solution for the treatment of both the stable wet and dry form of the condition. EyeMax can be used in both eyes and can be applied fast and easily. The innovative technology and unique optics of the EyeMax lens enhances the quality of the image supplied to the all areas of the macula permitting patients with AMD to make better use of the healthier parts of their retina. Advantages of the product include safer surgery, ease of implantation and significant improvement of vision for patients¹. Currently, the only other surgical options available for patients result in sub-optimal vision with high rates of complications. EyeMax is CE-marked in Europe and is exploring FDA approval in the US.

About age related macular degeneration (AMD)
LEH Pharma’s EyeMax product is aimed at improving the quality of life of patients with AMD, the western world’s biggest cause of blindness and the greatest unmet need in ophthalmology. AMD is a disorder affecting the central part of the retina, causing changes to central vision and making everyday tasks difficult.

EyeMax is aimed at two main patient populations: those who require cataract (where 1 in 3 patients or more may have some form of macular degeneration) and the non-cataract population including patients with AMD prior to cataract surgery or sufferers of other macular diseases such as diabetic eye disease.

¹ Published data from several European centres supports the effectiveness of EyeMax and can be found on the website here (www.iolamd.com/clinical-data). Most recently the European Journal of Ophthalmology found EyeMax safe and observed improvements after surgery above those of standard implants.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.